Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/009212ANTIBACTERIAL QUINOLONE DERIVATIVES
WO 21.01.2021
Int.Class C07D 519/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
519Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/ or C07D455/257
Appl.No PCT/EP2020/069978 Applicant IDORSIA PHARMACEUTICALS LTD Inventor RITZ, Daniel
The invention relates to compounds of Formula I which are useful as antibacterial agents in medicine.
2.WO/2021/009362BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING
WO 21.01.2021
Int.Class A61P 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Appl.No PCT/EP2020/070326 Applicant CTXT PTY LIMITED Inventor MORROW, Benjamin Joseph
A compound of formula (I); wherein: W is O or NH; A1 is CRA or N; A2 is CRB or N; A3 is CRC or N; A4 is CRD or N; where no more than two of A1, A2, A3, and A4 may be N; one or two of RA, RB, RC and RD, (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH; the remainder of R A, RB, RC and RD, (if present) are H; RN1 is H or Me; one of RC2 and RC3 is C(=O)NH2; the other is selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C2-4 alkenyl and C5heterocyclyl; RC1 and RC4 are independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C2-4 alkenyl and C5heterocyclyl.
3.WO/2021/010337LIGHT-EMITTING COMPOUND OR SALT THEREOF, AND POLARIZED LIGHT-EMITTING ELEMENT, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE CONTAINING SAME
WO 21.01.2021
Int.Class C07C 309/51
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
309Sulfonic acids; Halides, esters, or anhydrides thereof
01Sulfonic acids
28having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
45containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
51at least one of the nitrogen atoms being part of any of the groups X being a hetero atom, Y being any atom
Appl.No PCT/JP2020/027074 Applicant NIPPON KAYAKU KABUSHIKI KAISHA Inventor NAKAMURA Mitsunori
The invention is the light-emitting compound represented by formula (1), or a salt thereof.
4.WO/2021/011597PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENT
WO 21.01.2021
Int.Class A61K 9/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
Appl.No PCT/US2020/042044 Applicant OVID THERAPEUTICS INC. Inventor DURING, Matthew
Pharmaceutical formulations containing gaboxadol or a pharmaceutically acceptable salt thereof and methods of treating essential tremors, Tourette syndrome or Fragile X syndrome are provided. Pharmaceutical formulations herein include transdermal formulations and modified release dosage forms. In embodiments, a modified release dosage form includes an orally disintegrating dosage form. In embodiments, a modified release dosage form includes an extended release dosage form. In embodiments, a modified release dosage form includes a delayed release dosage form. In embodiments, a modified release dosage form includes a pulsatile release dosage form.
5.WO/2021/011747METHOD FOR TREATMENT OF MUSCULAR DYSTROPHY
WO 21.01.2021
Int.Class A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
Appl.No PCT/US2020/042285 Applicant CHILDREN’S NATIONAL MEDICAL CENTER Inventor JAISWAL, Jyoti
Disclosed herein are compositions that inhibit adipogenesis of a fibro/adipogenic precursor (FAP) cell and methods relating to treating, preventing, reducing, and/or inhibiting a muscular degenerative condition a muscular degenerative condition comprising administering said inhibitors.
6.WO/2021/011807POLYMORPHS OF (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
WO 21.01.2021
Int.Class A61P 9/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Appl.No PCT/US2020/042387 Applicant CYTOKINETICS, INC. Inventor TOM, Norma
Provided herein are polymorphs of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, compositions thereof, methods of preparation thereof, and methods of their uses.
7.WO/2021/007636STEREOISOMERS OF THE COMPOUND 3-(BENZO[D][1,3]DIOXOL-5-YL)-7-(1-HYDROXYPROPAN-2-YL)-1-(1H-INDOL-3-YL)-6,7-DIHYDRO-3H-OXAZOL[3,4-A]PYRAZINE-5,8-DIONE AND USE THEREOF AS AN ANTITUMOR AGENT AND PHOSPHODIESTERASE ENZYME INHIBITOR
WO 21.01.2021
Int.Class C07D 498/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/BR2020/050259 Applicant BIOLAB SANUS FARMACEUTICA LTDA Inventor SACURAI, Sérgio Luiz
The present invention relates to the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1H-indol-3-yl)-6,7-dihydro-3H-oxazol[3,4-a]pyrazine-5,8-dione of formula (I), and also to pharmaceutically acceptable stereoisomers, salts, solvates, hydrates, prodrugs and esters thereof, the stereoisomers being in their separate individual forms and/or in the form of racemic mixtures or non-racemic mixtures with diastereomeric excess in any proportion; to a pharmaceutical composition comprising at least one of the compounds described; to the use of said stereoisomers as an antitumour agent or phosphodiesterase enzyme inhibitor; and to the use of said stereoisomers for treating benign prostatic hyperplasia and cancer, more specifically prostate cancer.
8.WO/2021/008491BIPHENYL DERIVATIVES FOR BLOCKING PD-1/PD-L1 INTERACTION, PREPARATION METHOD THEREFOR AND USE THEREOF
WO 21.01.2021
Int.Class C07D 407/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
407Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/183
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
Appl.No PCT/CN2020/101646 Applicant ABBISKO THERAPEUTICS CO., LTD. Inventor YANG, Fei
Biphenyl derivatives having a structure of formula (I) and capable of blocking PD-1/PD-L1 interaction, a preparation method therefor and use thereof. The series of compounds can be widely used in the preparation of medicaments for preventing and/or treating cancers or tumors, immune-related diseases and disorders, communicable diseases, infectious diseases or metabolic diseases mediated by PD-1/PD-L1 signal pathways, and are expected to be developed into a new generation of PD-1/PD-L1 inhibitors.
9.WO/2021/009676IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS TOLL-LIKE RECEPTOR AGONSITS
WO 21.01.2021
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/IB2020/056605 Applicant PFIZER INC. Inventor AHMAD, Omar
The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
10.WO/2021/010681METHOD FOR PREPARING (3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-((4-HYDROXYMETHYLPHENYLAMINO)CARBONYL)-PYRROLE-1-YL)-3,5-DIHYDROXY HEPTANOIC ACID HEMICALCIUM SALT, AND METHOD FOR PREPARING INTERMEDIATES USED THEREIN
WO 21.01.2021
Int.Class C07D 207/337
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
30having two double bonds between ring members or between ring members and non-ring members
32with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
33with substituted hydrocarbon radicals, directly attached to ring carbon atoms
337Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Appl.No PCT/KR2020/009130 Applicant DAE WON PHARMACEUTICAL CO., LTD Inventor PARK, Eun-Jung
The present invention provides a method for preparing a (3R,5R)-7-(2-(4-flurophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrole-1-yl)-3,5-dihydroxy heptanoic acid hemicalcium salt. The preparation method of the present invention is performed in a convergent synthesis manner in which main structural moieties of a (3R,5R)-7-(2-(4-flurophenyl)-5-isopropyl-3-phenyl-4-((4-hydroxymethylphenylamino)carbonyl)-pyrrole-1-yl)-3,5-dihydroxy heptanoic acid hemicalcium salt are independently synthesized, and then coupled. Accordingly, related substances can be easily controlled and manufacturing time can be reduced, thus improving the productivity of a compound, and the yield of a final compound can also be increased.